Health
GSK Experimental Drug Reduces Severe Asthma Attacks in Trial
- Company has said treatment could exceed £3 billion in sales
- CEO Walmsley has focused on rebuilding GSK’s drug pipeline
This article is for subscribers only.
An experimental drug from GSK Plc reduced asthma attacks in late-stage trials, paving the way for a treatment that the British drugmaker forecasts could exceed £3 billion ($3.8 billion) in sales.
The drug, depemokimab, showed clinically meaningful reductions in severe asthma exacerbations over 52 weeks in patients with eosinophilic asthma, according to a statement Tuesday. That form of asthma is caused by high levels of white blood cells called eosinophils in the lungs’ airways.